Method of inhibition of vascular development using an antibody

Details Method of inhibition of vascular development using an antibody Method of inhibition of vascular development using an antibody

2005-08-09

2009-02-03

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S141100, C424S143100, C435S007100, C530S387100, C530S388150, C530S388220

Reexamination Certificate

active

07485297

ABSTRACT:
Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders.

REFERENCES:
patent: 5521073 (1996-05-01), Davis et al.
patent: 5851797 (1998-12-01), Valenzuela et al.
patent: 5955291 (1999-09-01), Alitalo et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6365154 (2002-04-01), Holmes et al.
patent: 6376653 (2002-04-01), Holmes et al.
patent: 6441137 (2002-08-01), Davis et al.
patent: 6492331 (2002-12-01), Godowski et al.
patent: 6551822 (2003-04-01), Godowski et al.
patent: 6586397 (2003-07-01), Godowski et al.
patent: 6627415 (2003-09-01), Davis et al.
patent: 7193064 (2007-03-01), Mikayama et al.
patent: 2002/0115173 (2002-08-01), Ben-Sasson
patent: 2002/0160478 (2002-10-01), Ben-Sasson
patent: 2003/0040463 (2003-02-01), Wiegand et al.
patent: 2003/0087393 (2003-05-01), O'Reilly et al.
patent: 2003/0113782 (2003-06-01), Karim et al.
patent: 2003/0152945 (2003-08-01), Deak et al.
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0166858 (2003-09-01), Davis et al.
patent: 2003/0180718 (2003-09-01), Pillutla et al.
patent: 2003/0219772 (2003-11-01), Kuyl et al.
patent: 2004/0067882 (2004-04-01), Alsobrook, II et al.
patent: 2004/0116330 (2004-06-01), Naito et al.
patent: 2004/0147449 (2004-07-01), Siemeister et al.
patent: 2004/0248781 (2004-12-01), Kerbel
patent: 753 015 (2000-08-01), None
patent: 1 225 233 (2002-07-01), None
patent: WO 93/14124 (1993-07-01), None
patent: WO 94/10197 (1994-05-01), None
patent: WO 95/21866 (1995-08-01), None
patent: WO 95/26364 (1995-10-01), None
patent: WO 98/07835 (1998-02-01), None
patent: WO 01/11086 (2001-02-01), None
patent: WO 01/47944 (2001-07-01), None
patent: WO 01/72339 (2001-10-01), None
patent: WO 01/88088 (2001-11-01), None
patent: WO 02/079492 (2002-10-01), None
patent: WO 02/102973 (2002-12-01), None
patent: WO 03/004529 (2003-01-01), None
patent: WO 03/064628 (2003-08-01), None
patent: WO 2005/016966 (2005-02-01), None
Hurwitz et al., Bevacizumab plus Irinotecan, fluorouracil and leucovorin fo metastatic colorectal cancer. N Eng. J Med. 350, 2335-2342, 2004.
Juha Partanen et al., “A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Exrtacellular Epidermal Growth Factor Homology Domains”Molecular and Cellular Biology, vol. 12, No. 4:pp. 1698-1707 (1992).
Davis et al. “Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning”Cell87:1161-1169 (1996).
International Search Report for PCT US2004/026116.
Chen-Konak et al., “Transcriptional and post-translation regulation of the Tiel receptor by fluid shear stress changes in vascular endothelial cells,” FASEB J.(2003) 17:2121-23.
Jones et al., “Tie receptors: new modulators of angiogenic and lymphangiogenic responses,” Nat Rev. Mol. Cell Biol., (Apr. 2001) 2(4):257-67.
Kontos et al., “The endothelial receptor tyrosine kinase Tiel activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis,” Mol. Cell Biol. Mar. 2002;22(6):1704-13.
Lin et al., “tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer,” Clin. Cancer Res. (Jul. 1999) 5(7):1745-51.
Loughna and Sato, “A combinatorial role of angiopoietin-1 and orphan receptor TIE1 pathways in establishing vascular polarity during angiogenesis,” Mol. Cell (2001) 7:233-39.
Marron et al., “Tie-1 receptor tyrosine kinase endodomain interaction with SHP2: potential signalling mechanisms and roles in angiogenesis,” Adv. Exp. Med. Biol. (2000) 476:35-46.
Marron et al., “Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2,” J Biol Chem. (Dec. 2000) 15;275(50):39741-6.
Puri et al., “The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells,” EMBO J. (Dec. 1, 1995) 14(23):5884-91.
Shahrara et al., “Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue,” Arthritis Res. (2002) 4:201-208.
Tsiamis et al., “Characterization and regulation of the receptor tyrosine kinase Tie-1 in platelets,” J. Vasc. Res. (Nov.-Dec. 2000) 37:437-42.
Barrios et al., “Length of the antibody heavy chain complementarity determining region 3 as specificity-determining factor,”J. Molec. Recog., 17:332-338, 2004.
Kobrin et al., “A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding,”J. Immunol., 146:2017-2020, 1991.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci., USA, 79:1979-1983, 1982.
International Search Report dated Nov. 2, 2007 from International Application No. PCT/US04/26116.

Affiliated with

Also associated with

Rating

Method of inhibition of vascular development using an antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inhibition of vascular development using an antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibition of vascular development using an antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4080022